Articles by Patrick Daly
Women with inherited bleeding disorders may need prophylaxis.
Non-Hispanic Black and White patients with MM had comparable links between risk factors and survival in the real world.
Heart failure with preserved ejection fraction (HFpEF) had worse mortality and acute kidney injury versus HF with reduced EF.
HSCT in the first line of therapy achieved consistent survival benefits across subgroups of patients with multiple myeloma.
In hospitalizations for multiple myeloma, mortality and disability rates were disparately impacted by socioeconomic status.
Obesity was associated with a higher response rate and faster best response in patients with multiple myeloma.
Black patients with multiple myeloma achieved similar or superior survival rates compared with White patients in studies.
Older age, male sex, and racial minority status were associated with mortality within 2 years of multiple myeloma diagnosis.
Ide-cel exhibited some safety and response differences across patients with multiple myeloma in different racial groups.
Modifying or ceasing MM treatment based on negative MRD status may be a promising approach for newly diagnosed patients.
White patients with MM and diabetes showed worse survival outcomes, but this association was not found in Black patients.
Phase 1 data showed promising outcomes with elranatamab in MM, and authors recommend a phase 2 dose of 76 mg weekly.
Patients with MM and renal impairment on DVd showed safety and efficacy comparable with patients without renal impairment.
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
IMWG multiple myeloma treatment guidelines informed by studies with a major lack of Black patients, study finds.
Daratumumab added to carfilzomib-lenalidomide-dexamethasone triplet therapy for multiple myeloma improved MRD and survival.
Elotuzumab combination therapy had promising activity and tolerability for patients with multiple myeloma in first relapse.
Selinexor-based triplet regimens were effective in patients with multiple myeloma who were refractory to anti-CD38 therapies.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.